Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Rheumatoid Arthritis
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Rheumatoid Arthritis
    Heavy Birth Weight Doubles Risk of Developing Rheumatoid Arthritis - (DGNews)
    EMEA Recommends Updated Label Warnings for Etoricoxib-Containing Drugs - (DGNews)
    TopAbstracts in Rheumatoid Arthritis 06/26/2008 - (DGNews)
    Etanercept Plus Methotrexate Prevents Joint Damage in Early Active Rheumatoid Arthritis: Presented at EULAR - (DGDispatch)
    Abatacept and Infliximab Improve ACR and LDAS in Methotrexate-Refractory RA Patients - (DGNews)

    News archive

     Recent webcasts/CME - Rheumatoid Arthritis
    • Beyond Efficacy and Safety in Rheumatoid Arthritis Treatment: Quality-of-Life Outcomes With Newer Biologics in RA
    • Long-Term Data on Abatacept and Rituximab Show Continued Efficacy in Rheumatoid Arthritis
    • Are Rituximab and Abatacept Safe Over the Long Term in Rheumatoid Arthritis?
    • Pathology and Treatment of Rheumatoid Arthritis: The Role of IL-6 in Inflammation and Rheumatoid Arthritis
      Systemic Pathology of Rheumatoid Arthritis

      Webcasts/CME archive

       Recent cases - Rheumatoid Arthritis
        Rheumatoid Nodule of the Thyrohyoid Membrane: A Case Report
        Recurrent Pneumothorax in a Patient with Rheumatoid Arthritis on Leflunomide Treatment: Case Report and Overview of the Literature
        Spontaneous Esophageal Perforation in a Patient with Achalasia Cardia and Rheumatoid Arthritis
        Rheumatoid Arthritis in Thalassemia Intermedia: Coincidence or Association?
        Gamma/Delta T-cell Receptor Type Granular Lymphocyte Proliferative Disorder Associated with Rheumatoid Arthritis

        Cases archive
          




        my personal edition > rheumatoid arthritis > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        People With Rheumatoid Arthritis Underuse Prophylactic Aspirin: Presented at ACR

        By Paula Moyer

        SAN DIEGO, CA -- November 21, 2005 -- People with rheumatoid arthritis (RA) are less likely to use low-dose aspirin for prevention of cardiovascular events than are people with other noninflammatory disorders, according to research presented here at the American College of Rheumatology Annual Scientific Meeting (ACR).

        In addition, the researchers said, fewer than 20% of patients with RA in this study were using low-dose aspirin. The investigators speculated that, between the patients' specialty care and primary care, aspirin prophylaxis may be falling under the radar.

        "Rheumatologists --- may be assuming preventive issues are being addressed by the primary physician, whereas primary physicians may not be aware that those with rheumatoid arthritis are under additional cardiac risk that may warrant aspirin use," said principal investigator Lee Colglazier, MD, practicing rheumatologist, Compass Health Care, Crestview Hills, Kentucky, at a briefing on November 16th.

        "Whatever the cause, rheumatologists should make sure that their patients are receiving the recommended care for the prevention and treatment of cardiovascular disorders," said Dr. Colglazier, who was a rheumatology fellow at Wake Forest University School of Medicine in Winston-Salem, North Carolina, when he conducted the study.

        Guidelines from the United States Preventive Services Task Force of the Department of Health and Human Services recommend that adults take low-dose aspirin daily (81 to 325 mg/day) if they have a high 10-year risk of myocardial infarction.

        According to previous research, inflammatory diseases are a known risk factor for cardiovascular disease.

        The investigators conducted their study to determine the extent to which patients with RA were getting the recommended prophylactic care.

        For the 3-year period ending in 2004, the investigators surveyed 18,123 patients every 6 months as part of a study of rheumatic disease outcomes. Among these patients, 14,114 had RA and 4,009 had noninflammatory rheumatic disorders.

        When the investigators adjusted the results for age and sex, subjects with RA had an odds ratio (OR) of 1.7 for myocardial infarction.

        The results also show that patients with RA were less likely to be taking prophylactic aspirin than were subjects with other rheumatic disorders (OR 0.67). Among those with RA, 8.14% were taking low-dose aspirin compared with 25.1% of those with other rheumatoid disorders.

        Even after the investigators adjusted for age and sex and added the covariate of myocardial infarction history, the OR for taking aspirin remained the same, the investigators reported. Aspirin prophylaxis was always lower in patients with RA, Dr. Colglazier reported.

        Within the group with RA, men had an OR of 1.6 for aspirin use. Subjects using cyclooxygenase 2 inhibitors (COX-2 inhibitors) were as likely to use aspirin, with an OR of 1.06, and whites and those with higher education were more likely to use aspirin.

        Factors associated with less aspirin use were use of nonspecific nonsteroidal anti-inflammatory drugs (NSAIDs, OR of 0.89); worse functional status (OR of 0.92); increased pain (OR of 0.98); fibromyalgia (OR of 0.91); and prednisone use (OR of 0.94).

        The best predictive model of prophylactic aspirin use in RA consisted of NSAID use, majority ethnicity, functional status, age, sex, myocardial infarction history, and history of hypertension. However, even these variables taken together had poor predictability for prophylactic aspirin use, the investigators reported.


        [Presentation title: Rheumatoid Arthritis (RA) Patients are Less Likely to be Treated With Prophylactic Aspirin Despite an Increased Risk of Myocardial Infarction. Abstract 1904]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send